Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice.

Lundgren, Taran S; Denning, Gabriela; Stowell, Sean R; Spencer, H Trent; Doering, Christopher B

Lundgren, Taran S; Denning, Gabriela; Stowell, Sean R; Spencer, H Trent; Doering, Christopher B.

Afiliação

Lundgren TS; Graduate Program in Molecular and Systems Pharmacology, Laney Graduate School, Emory University, Atlanta, GA.
Denning G; Expression Therapeutics, Inc., Tucker, GA.
Stowell SR; Joint Program in Transfusion Medicine, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and.
Spencer HT; Expression Therapeutics, Inc., Tucker, GA.
Doering CB; Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA.

Blood Adv ; 6(8): 2628-2645, 2022 04 26.

Article em En | MEDLINE | ID: mdl-35286375

Assuntos

Hemofilia A; Hemostáticos; Animais; Fator VIII/genética; Fator VIII/uso terapêutico; Terapia Genética; Hemofilia A/genética; Hemofilia A/terapia; Camundongos; Transgenes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemostáticos / Hemofilia A Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google